NCT05145218 - A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | Biotech Hunter

Enrollment

405

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions

Recurrent Platinum-resistant Ovarian Cancer

Interventions

DRUG

Anlotinib Hydrochloride Capsules

Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.

DRUG

Paclitaxel injection

Paclitaxel is a novel anti-microtubule agent.

DRUG

TQB2450 injection

TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.

Trial Locations (2)

RECRUITING

AnYang Tumor Hospital, Anyang

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou